Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment

Clin Infect Dis. 2004 Oct 1;39(7):e70-3. doi: 10.1086/424018. Epub 2004 Sep 8.

Abstract

Conventional antifungal therapy for fungal endocarditis has been associated with a poor cure rate. Therefore, combined medical and surgical therapy has been recommended. However, new potent antifungal agents, such as echinocandins, could increase the medical options and, in some cases, avoid the need for surgery. We report a case of Candida endocarditis treated successfully without valve replacement with intravenous liposomal amphotericin B (total dose, 4 g) and intravenous caspofungin (a 100-mg loading dose followed by 50 mg per day for 8 weeks) as induction therapy and intravenous caspofungin (100 mg 3 times per week for 12 weeks) as maintenance therapy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Candida glabrata*
  • Candidiasis / diagnosis*
  • Candidiasis / microbiology
  • Caspofungin
  • Drug Therapy, Combination
  • Echinocandins
  • Endocarditis / drug therapy*
  • Endocarditis / microbiology*
  • Female
  • Humans
  • Lipopeptides
  • Peptides, Cyclic / therapeutic use*

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • Amphotericin B
  • Caspofungin